Compare AMG & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMG | BIO |
|---|---|---|
| Founded | 1993 | 1952 |
| Country | United States | United States |
| Employees | 5600 | 7450 |
| Industry | Investment Managers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 6.9B |
| IPO Year | N/A | N/A |
| Metric | AMG | BIO |
|---|---|---|
| Price | $305.23 | $312.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $384.00 | $339.75 |
| AVG Volume (30 Days) | 265.6K | ★ 471.8K |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.01% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.98 | $2.74 |
| Revenue Next Year | $9.34 | $3.20 |
| P/E Ratio | $14.55 | ★ $9.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $172.54 | $211.43 |
| 52 Week High | $334.78 | $343.12 |
| Indicator | AMG | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 68.29 |
| Support Level | $290.53 | $293.88 |
| Resistance Level | $308.06 | $330.54 |
| Average True Range (ATR) | 7.63 | 9.86 |
| MACD | 0.21 | 6.66 |
| Stochastic Oscillator | 64.57 | 90.63 |
Affiliated Managers Group offers investment strategies to investors through its network of affiliates. The firm typically buys a majority interest in small to mid-size boutique asset managers, receiving a fixed percentage of revenue from these firms in return. Affiliates operate independently, with AMG providing strategic, operational, and technology support, as well as global distribution. At the end of December 2025, AMG's affiliate network—which includes firms like Abacus Capital and Pantheon dedicated to private markets (which accounted for 18% of AUM), AQR Capital and Capula Investment Management in liquid alternatives (28%), and Harding Loevner, Tweedy Browne, Parnassus, and Yacktman in equities, multi-asset, and bond strategies (54%)—had $813.3 billion in managed assets.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.